NICE recommends Vectibix for previously untreated metastatic colorectal cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Institute for Health and Care Excellence issued a Final Appraisal Determination recommending panitumumab as an option for patients with previously untreated, RAS wild-type metastatic colorectal cancer in adults in combination with the FOLFOX or FOLFIRI chemotherapy regimens.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

Login